S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
LON:DDDD

4D pharma Share Forecast, Price & News

GBX 124.78
+5.28 (+4.41 %)
(As of 03/8/2021 12:51 PM ET)
Add
Compare
Today's Range
119
Now: GBX 124.78
126.50
50-Day Range
113.50
MA: GBX 127.49
147
52-Week Range
23.50
Now: GBX 124.78
183
Volume877,630 shs
Average Volume2.24 million shs
Market Capitalization£164.08 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease. It also develops immuno-oncology products comprising MRx0518, MRx0573, and MRx1299 for solid tumors, and MRx0518 for pancreatic cancer; respiratory products, such as MRx-4DP0004 for asthma and COVID-19; central nervous system products, including MRx0005 and MRx0029 for neurodegeneration; and platform products comprising vaccines and autoimmune. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.

Headlines

4D Pharma Presents Update on Oncology Program
February 3, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-113-8950130
Employees127
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£486,000.00
Cash FlowGBX 9.61 per share
Book ValueGBX 28.70 per share

Profitability

Miscellaneous

Market Cap£164.08 million
Next Earnings Date5/24/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.56 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
GBX 124.78
+5.28 (+4.41 %)
(As of 03/8/2021 12:51 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DDDD News and Ratings via Email

Sign-up to receive the latest news and ratings for DDDD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











4D pharma (LON:DDDD) Frequently Asked Questions

What stocks does MarketBeat like better than 4D pharma?

Wall Street analysts have given 4D pharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 4D pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is 4D pharma's next earnings date?

4D pharma is scheduled to release its next quarterly earnings announcement on Monday, May 24th 2021.
View our earnings forecast for 4D pharma
.

How were 4D pharma's earnings last quarter?

4D pharma plc (LON:DDDD) released its quarterly earnings results on Wednesday, September, 30th. The company reported ($14.06) EPS for the quarter.
View 4D pharma's earnings history
.

How has 4D pharma's stock been impacted by COVID-19?

4D pharma's stock was trading at GBX 48.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DDDD stock has increased by 155.2% and is now trading at GBX 124.78.
View which stocks have been most impacted by COVID-19
.

Who are 4D pharma's key executives?

4D pharma's management team includes the following people:
  • Mr. Duncan Joseph Peyton, CEO & Exec. Director (Age 51, Pay $102k)
  • Dr. Alexander James Stevenson, Chief Scientific Officer & Exec. Director (Age 49, Pay $102k)
  • Mr. Stephen Dunbar, Fin. Director
  • Fay Weston, Head of Investor Relations
  • Mr. Laurence Dale, Gen. Counsel & Company Sec.
  • Dr. John D. Weinberg, Chief Medical Officer (Age 54)

Who are some of 4D pharma's key competitors?

What other stocks do shareholders of 4D pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 4D pharma investors own include Amigo (AMGO), Adamis Pharmaceuticals (ADMP), American Airlines Group (AAL), The Boeing (BA), Cineworld Group (CINE), Cray (CRAY), Omega Diagnostics Group (ODX), Oracle (ORCL), Senseonics (SENS) and Tullow Oil (TLW).

What is 4D pharma's stock symbol?

4D pharma trades on the London Stock Exchange (LON) under the ticker symbol "DDDD."

How do I buy shares of 4D pharma?

Shares of DDDD and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is 4D pharma's stock price today?

One share of DDDD stock can currently be purchased for approximately GBX 124.78.

How much money does 4D pharma make?

4D pharma has a market capitalization of £164.08 million and generates £486,000.00 in revenue each year.

How many employees does 4D pharma have?

4D pharma employs 127 workers across the globe.

What is 4D pharma's official website?

The official website for 4D pharma is www.4dpharmaplc.com.

Where are 4D pharma's headquarters?

4D pharma is headquartered at 9 Bond Court, LEEDS, LS1 2JZ, United Kingdom.

How can I contact 4D pharma?

4D pharma's mailing address is 9 Bond Court, LEEDS, LS1 2JZ, United Kingdom. The company can be reached via phone at +44-113-8950130.


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.